The API Interacts with Therapeutic Targets
related to Overactive Innate Immunity
Inhibition of Neutrophil Activation with reduction in Neutrophil Extracellular Traps (NETs), limiting progression of arterial thrombosis in Acute Ischemic Stroke (AIS) and Acute Coronary Syndrome (ACS).
Inhibition of Fibrin accumulation in Thromboses, limiting acute and chronic damage in Traumatic Brain Injury and facilitating successful thrombectomy in Large Vessel Occlusion (LVO) AIS.
Inhibition of Extracellular Vesicle (EV) Release following TBI with protection of the Blood Brain Barrier (BBB) and prevention of post-traumatic cerebral edema.
Prevention of Microbleeding associated with TBI associated loss of integrity of the BBB.
